Award recognizes his contributions to basic and clinical research.
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.
From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.
In Year Three, GAP Trial Network Is Starting to Hum Getting to Go: GAP-Net Sets Sight on Faster Start Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s ...
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
Atomic resolution structures of tau filaments from three people with CTE revealed a common strain of tau induced by chronic head injuries.
Futility analysis predicts failure to reach primary endpoint.
Perturbations in the hormone correlate with memory problems. But does FGF23 act in the brain, or affect cognition indirectly via the kidneys?
Exposing AD mice to multisensory gamma therapy induced 40-Hz waves in their brains, plus effects on amyloid, tau, microglia, blood vessels, and cognitive function.
Among British civil servants, the quality of their diet did not correlate with their risk of developing dementia cognitive decline over 25 years.
IBM researchers in Australia identify a combination of four proteins in plasma that predicts amyloid positivity in cerebrospinal fluid, and correlates with progression to AD.
Deleting BACE1 with CRISPR nanocomplexes tempered Aβ pathology and boosted memory.
Liquid beads of TDP-43 form independently of stress granules and sequester proteins needed for nucleocytoplasmic transport.
When the agency sent warning letters to 17 companies that falsely advertised cures and preventions for AD, most took down exaggerated claims. But can regulations stay ahead of the market?
In people at intermediate risk for cardiovascular disease, the meds had no effect on cognitive decline over six years.